Michael Schmidt
Stock Analyst at Guggenheim
(2.21)
# 2,609
Out of 4,810 analysts
101
Total ratings
41.33%
Success rate
-5.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ONC BeiGene | Reiterates: Buy | $348 | $238.84 | +45.70% | 1 | Apr 10, 2025 | |
| NBTX Nanobiotix | Maintains: Buy | $12 → $8 | $3.41 | +134.60% | 2 | Apr 4, 2025 | |
| CMPX Compass Therapeutics | Reiterates: Buy | $12 | $1.70 | +605.88% | 2 | Apr 2, 2025 | |
| ADCT ADC Therapeutics | Maintains: Buy | $10 → $7 | $1.21 | +478.51% | 4 | Mar 31, 2025 | |
| MRUS Merus | Reiterates: Buy | $109 | $43.22 | +152.20% | 5 | Mar 28, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Buy | $3 → $1.75 | $0.25 | +601.40% | 3 | Mar 26, 2025 | |
| VSTM Verastem | Maintains: Buy | $13 → $14 | $4.81 | +191.06% | 3 | Mar 24, 2025 | |
| IMNM Immunome | Maintains: Buy | $35 → $25 | $7.40 | +237.84% | 2 | Mar 20, 2025 | |
| INCY Incyte | Downgrades: Neutral | $92 | $58.46 | +57.37% | 5 | Mar 18, 2025 | |
| ARVN Arvinas | Maintains: Buy | $57 → $32 | $7.58 | +322.16% | 4 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $33.74 | - | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $18.63 | +141.55% | 1 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $5.04 | - | 5 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $36.54 | +14.94% | 10 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $0.50 | - | 1 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $37.59 | +107.50% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $81.45 | - | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $4.17 | +379.62% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $87 | $36.32 | +139.54% | 2 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $1.27 | +529.92% | 3 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $27.31 | - | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.35 | - | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.29 | - | 2 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 | $0.35 | +1,908.61% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.46 | - | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $34 | $9.54 | +256.39% | 4 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $42 | $11.33 | +270.70% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 | $0.59 | +3,280.66% | 3 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $19.51 | - | 2 | Jan 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.19 | +2,000.84% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $4.43 | +577.20% | 1 | Jul 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $2.61 | +895.56% | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.46 | - | 2 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.47 | - | 4 | Mar 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $80 | $27.82 | +187.56% | 5 | Feb 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.06 | - | 6 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $4 → $5.5 | $3.16 | +74.05% | 2 | Nov 7, 2017 |
BeiGene
Apr 10, 2025
Reiterates: Buy
Price Target: $348
Current: $238.84
Upside: +45.70%
Nanobiotix
Apr 4, 2025
Maintains: Buy
Price Target: $12 → $8
Current: $3.41
Upside: +134.60%
Compass Therapeutics
Apr 2, 2025
Reiterates: Buy
Price Target: $12
Current: $1.70
Upside: +605.88%
ADC Therapeutics
Mar 31, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $1.21
Upside: +478.51%
Merus
Mar 28, 2025
Reiterates: Buy
Price Target: $109
Current: $43.22
Upside: +152.20%
Adaptimmune Therapeutics
Mar 26, 2025
Maintains: Buy
Price Target: $3 → $1.75
Current: $0.25
Upside: +601.40%
Verastem
Mar 24, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $4.81
Upside: +191.06%
Immunome
Mar 20, 2025
Maintains: Buy
Price Target: $35 → $25
Current: $7.40
Upside: +237.84%
Incyte
Mar 18, 2025
Downgrades: Neutral
Price Target: $92
Current: $58.46
Upside: +57.37%
Arvinas
Mar 13, 2025
Maintains: Buy
Price Target: $57 → $32
Current: $7.58
Upside: +322.16%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $33.74
Upside: -
Mar 10, 2025
Initiates: Buy
Price Target: $45
Current: $18.63
Upside: +141.55%
Feb 26, 2025
Reiterates: Buy
Price Target: n/a
Current: $5.04
Upside: -
Feb 12, 2025
Reiterates: Buy
Price Target: $42
Current: $36.54
Upside: +14.94%
Jan 22, 2025
Reiterates: Buy
Price Target: n/a
Current: $0.50
Upside: -
Jan 8, 2025
Maintains: Buy
Price Target: $80 → $78
Current: $37.59
Upside: +107.50%
Dec 11, 2024
Reiterates: Buy
Price Target: n/a
Current: $81.45
Upside: -
Dec 6, 2024
Reiterates: Buy
Price Target: $20
Current: $4.17
Upside: +379.62%
Dec 3, 2024
Maintains: Buy
Price Target: $82 → $87
Current: $36.32
Upside: +139.54%
Nov 15, 2024
Maintains: Buy
Price Target: $12 → $8
Current: $1.27
Upside: +529.92%
Oct 7, 2024
Downgrades: Neutral
Price Target: n/a
Current: $27.31
Upside: -
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.35
Upside: -
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.29
Upside: -
Feb 29, 2024
Upgrades: Buy
Price Target: $7
Current: $0.35
Upside: +1,908.61%
Jan 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.46
Upside: -
Nov 8, 2023
Maintains: Buy
Price Target: $40 → $34
Current: $9.54
Upside: +256.39%
Jul 25, 2023
Maintains: Buy
Price Target: $40 → $42
Current: $11.33
Upside: +270.70%
Jun 27, 2023
Downgrades: Neutral
Price Target: $20
Current: $0.59
Upside: +3,280.66%
Jan 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $19.51
Upside: -
Aug 10, 2021
Initiates: Buy
Price Target: $25
Current: $1.19
Upside: +2,000.84%
Jul 19, 2021
Initiates: Buy
Price Target: $30
Current: $4.43
Upside: +577.20%
May 18, 2021
Initiates: Buy
Price Target: $26
Current: $2.61
Upside: +895.56%
Apr 28, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.46
Upside: -
Mar 5, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $4.47
Upside: -
Feb 15, 2019
Upgrades: Outperform
Price Target: $80
Current: $27.82
Upside: +187.56%
Jan 17, 2019
Initiates: Outperform
Price Target: n/a
Current: $4.06
Upside: -
Nov 7, 2017
Maintains: Market Perform
Price Target: $4 → $5.5
Current: $3.16
Upside: +74.05%